Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy

By afschroeder • November 30, 2025

Wang Y, Guan Y, Abbas AR, Sano Y, Jain S, Lu S, Hamidi H, Koeppen H, Azuma Y, Kayukawa Y, Shinozuka J, Pochiraju A, Webster JD, Rieder N, Dietmann G, Cannarile M, Cotter C, Hack SP, Cha E, Ishiguro T, Llovet JM, Zhu AX, Finn RS. Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy. Cell Rep Med. 2025 Nov 28:102473. doi: 10.1016/j.xcrm.2025.102473. Epub ahead of print. PMID: 41317730.

Tags: Atezolizumab, Bevacizumab, HCC, Hematology/Oncology, immunotherapy, liver cell lineages, mechanisms of response and resistance, molecular subtype, Publications

CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer

Alcantar JM, Chuang FL, Kim DD. CDK4/6 Inhibitor-Mediated Cutaneous Toxicity in Breast Cancer. Cureus. 2026 Mar 25;18(3):e105839. doi: 10.7759/cureus.105839. PMID: 42037944; PMCID: PMC13108622.

Durvalumab Plus Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD

Cho BC, Nishio M, Ahn MJ, García-Campelo R, Ponce S, Baik C, Salgia R, Kim SW, Lee JS, Yoshida T, Yu HA, Goldberg SB, Johannes[...]

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

Muñoz J, Locke FL, Reagan PM, Goy A, Jacobson CA, Hill BT, Timmerman JM, Flinn IW, Miklos DB, Pagel JM, Kersten MJ, Forcade E, Topp[...]